Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast ; volume:40 ; number:8 ; day:16 ; month:6 ; year:2023 ; pages:3291-3303 ; date:8.2023
Advances in therapy ; 40, Heft 8 (16.6.2023), 3291-3303, 8.2023
- Creator
-
Landgren, Ola
Nadeem, Omar
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-023-02551-9
- URN
-
urn:nbn:de:101:1-2023101308095555870469
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Landgren, Ola
- Nadeem, Omar
- SpringerLink (Online service)
Other Objects (12)
ASH highlights 2022—multiple myeloma
Bispecific antibodies in the treatment of multiple myeloma
ASH 2018—Highlights in Multiple Myeloma
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023—A Podcast
Multiple myeloma: my highlights at ASH 2020
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Infectious complications of bispecific antibody therapy in patients with multiple myeloma
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
Bispecific antibodies
Bispecific antibodies
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
ASH highlights 2022—multiple myeloma
Bispecific antibodies in the treatment of multiple myeloma
ASH 2018—Highlights in Multiple Myeloma
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023—A Podcast
Multiple myeloma: my highlights at ASH 2020
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Infectious complications of bispecific antibody therapy in patients with multiple myeloma
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
Bispecific antibodies
Bispecific antibodies
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
ASH highlights 2022—multiple myeloma
Bispecific antibodies in the treatment of multiple myeloma
ASH 2018—Highlights in Multiple Myeloma
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023—A Podcast
Multiple myeloma: my highlights at ASH 2020
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Infectious complications of bispecific antibody therapy in patients with multiple myeloma
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
Bispecific antibodies
Bispecific antibodies
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma